Cytokinetics Inc. (CYTK) Financial Statements
Historical financial data — 39 statements covering FY2016–FY2025
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential...
Cytokinetics Inc.'s revenue increased 376.6% year over year, from $18.5M to $88.0M.
Net income decreased 33.2% over the same period, from $-589.5M to $-785.0M.
Over the 9-year period from FY2016 to FY2025, revenue declined by 17% in total.
Total debt increased by 164.3% to $246.4M.
Operating cash flow declined 28.8% to $-510.0M.
Cytokinetics Inc. maintains a negative net profit margin of -891.7%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $1.1M+186.8% | $-279.0M | N/A | $-256.4M | $-228.8M | $1.52B | $92.8M | $108.5M |
| Q3 FY2024 | $463.0K-57.3% | $-160.5M | N/A | $-140.8M | $-101.5M | $1.44B | $93.0M | $-13.9M |
| Q4 FY2024 | $16.9M+3555.9% | $-150.0M | N/A | $-139.0M | $-65.6M | $1.40B | $93.2M | $-135.4M |
| Q1 FY2025 | $1.6M-90.7% | $-161.4M | N/A | $-155.6M | $-131.6M | $1.26B | $92.0M | $-266.4M |
| Q2 FY2025 | $66.8M+4128.6% | $-134.3M | N/A | $-111.5M | $-128.3M | $1.23B | $159.1M | $-368.7M |
| Q3 FY2025 | $1.9M-97.1% | $-306.2M | N/A | $-166.8M | $-107.5M | $1.44B | $158.7M | $-521.1M |
| Q4 FY2025 | $17.8M+817.1% | $-183.1M | N/A | $-178.4M | $-142.6M | $1.42B | $246.4M | $-659.6M |
| Q1 FY2026 | $19.4M+9.0% | $-206.0M | N/A | $-183.6M | $-145.5M | $1.27B | $247.2M | $-826.6M |
Balance Sheet Summary (Latest Period)
Cytokinetics Inc. (CYTK) Financial Statements & Revenue History
Cytokinetics Inc. (CYTK) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $67.90 with a market capitalization of $9. This page provides 39 historical financial statements for Cytokinetics Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Cytokinetics Inc. reported revenue of $88 million, representing 376.6% year-over-year growth. The net profit margin of -891.7% indicates the company is currently unprofitable..
CYTK Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Cytokinetics Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether CYTK is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track CYTK's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Cytokinetics Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of CYTK's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use CYTK Financial Data
Investors use Cytokinetics Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare CYTK's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how CYTK's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View CYTK's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Cytokinetics Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.CYTK trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.